DEprescribing: Perceptions of PAtients living with advanced cancer. A multicentre, prospective mixed observational study protocol.
Adrien Evin, Marianne Bourdon, Pierre Nizet...
https://pubmed.ncbi.nlm.nih.gov/39163415Actively Recruiting
Led by Nantes University Hospital · Updated on 2026-02-11
325
Participants Needed
8
Research Sites
95 weeks
Total Duration
N
Nantes University Hospital
Lead Sponsor
F
Fondation de France
Collaborating Sponsor
This research aims to understand patients' views on deprescribing medications in palliative cancer care, focusing on the challenges of polymedication that can reduce quality of life and increase healthcare costs. The study also investigates factors influencing patients' beliefs about deprescribing and evaluates a questionnaire, the rPATD, to measure these perceptions in this specific population. The study consists of two main parts over three years. First, about 25 patients will participate in individual semi-structured interviews over eight months to gather detailed qualitative data. Then, a larger group of 300 patients will complete self-administered questionnaires, including the rPATD and the BMQ, over twelve months to quantify attitudes toward deprescribing. An additional questionnaire on health literacy will also be given during this second phase. Participants will be involved through interviews and questionnaires assessing their perceptions, beliefs, and literacy related to medication use and deprescribing. The researchers will analyze these responses to identify different patient profiles and factors affecting attitudes toward medication reduction. Outcomes focus on patients' perceptions at study entry, measured using validated tools, without treatment interventions. The study is observational and aims to improve deprescribing approaches in palliative oncology care.
CONDITIONS
DEprescribing: Perceptions of PAtients Living With Advanced Cancer
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) to determine eligibility and obtain consent
Duration - Up to 8 months
Participants take part in semi-directed individual interviews to explore their perceptions of deprescribing in palliative cancer care.
1 to 2 interviews (in-person or remote) depending on participant availability
Duration - Up to 12 months
Participants complete self-administered questionnaires assessing their perceptions of treatments, beliefs about medicines, and health literacy.
1 visit to complete questionnaires (in-person or remote)
Total: 8 locations
1
CHD Vendée
La Roche-sur-Yon, France, 85000
Not Yet Recruiting
2
Hospices Civils de Lyon
Lyon, France
Not Yet Recruiting
3
CHU de Nantes
Nantes, France, 44093
Actively Recruiting
4
USP - Maison de Nicodème
Nantes, France
Not Yet Recruiting
5
Hôpital Institut CURIE
Paris, France, 75005
Not Yet Recruiting
6
Institut de Cancérologie de l'Ouest
Saint-Herblain, France, 44800
Not Yet Recruiting
7
CH ST Nazaire
Saint-Nazaire, France, 44600
Not Yet Recruiting
8
CHRU Tours
Tours, France
Not Yet Recruiting
A
Adrien EVIN, MCU-PH
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Adrien Evin, Marianne Bourdon, Pierre Nizet...
https://pubmed.ncbi.nlm.nih.gov/39163415